$OBIO
Orchestra Biomed Holdings Inc

2024 Q4 Form 10-Q Financial Statement

#000155837024015313 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $987.0K
YoY Change 135.56%
Cost Of Revenue $68.00K
YoY Change 65.85%
Gross Profit $919.0K
YoY Change 143.12%
Gross Profit Margin 93.11%
Selling, General & Admin $5.666M
YoY Change -10.69%
% of Gross Profit 616.54%
Research & Development $11.60M
YoY Change 35.49%
% of Gross Profit 1261.7%
Depreciation & Amortization $76.00K
YoY Change 7.04%
% of Gross Profit 8.27%
Operating Expenses $17.26M
YoY Change 15.83%
Operating Profit -$16.34M
YoY Change 12.52%
Interest Expense $916.0K
YoY Change -24.3%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$15.43M
YoY Change 15.85%
Net Earnings / Revenue -1562.92%
Basic Earnings Per Share -$0.41
Diluted Earnings Per Share -$0.41
COMMON SHARES
Basic Shares Outstanding 38.01M 37.82M
Diluted Shares Outstanding 37.62M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $25.61M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $234.0K
Prepaid Expenses
Receivables $115.0K
Other Receivables
Total Short-Term Assets $68.55M
YoY Change -37.79%
LONG-TERM ASSETS
Property, Plant & Equipment $1.254M
YoY Change -7.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $6.766M
YoY Change 9.7%
TOTAL ASSETS
Total Short-Term Assets $68.55M
Total Long-Term Assets $6.766M
Total Assets $75.32M
YoY Change -35.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.723M
YoY Change 49.94%
Accrued Expenses $7.034M
YoY Change 63.54%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.22M
YoY Change -24.47%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $16.22M
Total Long-Term Liabilities
Total Liabilities $29.10M
YoY Change -20.71%
SHAREHOLDERS EQUITY
Retained Earnings -$293.7M
YoY Change 24.43%
Common Stock $4.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity
YoY Change
Total Liabilities & Shareholders Equity $75.32M
YoY Change -35.27%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$15.43M
YoY Change 15.85%
Depreciation, Depletion And Amortization $76.00K
YoY Change 7.04%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-15426000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13316000
us-gaap Net Income Loss
NetIncomeLoss
-44869000
us-gaap Net Income Loss
NetIncomeLoss
-36302000
CY2024Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
121000
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
19000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
108000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-69000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15305000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13297000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44761000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36371000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68043000
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
2000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2588000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-13463000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
57188000
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-15000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2761000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
171000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-15980000
dei Entity Central Index Key
EntityCentralIndexKey
0001814114
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
obio Liabilities Transfers Within Levels
LiabilitiesTransfersWithinLevels
0
CY2023 obio Liabilities Transfers Within Levels
LiabilitiesTransfersWithinLevels
0
dei Entity Registrant Name
EntityRegistrantName
Orchestra BioMed Holdings, Inc.
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2024Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P24M
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39421
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
92-2038755
dei Entity Address Address Line1
EntityAddressAddressLine1
150 Union Square Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
New Hope
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
18938
dei City Area Code
CityAreaCode
215
dei Local Phone Number
LocalPhoneNumber
862-5797
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
OBIO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38013526
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25605000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30559000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
41321000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
56968000
CY2023Q4 us-gaap Other Short Term Investments
OtherShortTermInvestments
68000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
115000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
99000
CY2024Q3 us-gaap Inventory Net
InventoryNet
234000
CY2023Q4 us-gaap Inventory Net
InventoryNet
146000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1278000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1274000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
68553000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
89114000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1254000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1279000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1714000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1555000
CY2024Q3 us-gaap Other Investments
OtherInvestments
2495000
CY2023Q4 us-gaap Other Investments
OtherInvestments
2495000
CY2024Q3 obio Deposits And Other Assets
DepositsAndOtherAssets
1303000
CY2023Q4 obio Deposits And Other Assets
DepositsAndOtherAssets
769000
CY2024Q3 us-gaap Assets
Assets
75319000
CY2023Q4 us-gaap Assets
Assets
95212000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4723000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2900000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7034000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5149000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
395000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
649000
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4066000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2510000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
16218000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11208000
CY2024Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
11439000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
14923000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1443000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1038000
CY2024Q3 us-gaap Liabilities
Liabilities
29100000
CY2023Q4 us-gaap Liabilities
Liabilities
27169000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37942905
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37942905
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35777412
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35777412
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
339840000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
316903000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
98000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-293723000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-248854000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
46219000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68043000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75319000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95212000
CY2024Q3 us-gaap Revenues
Revenues
987000
CY2023Q3 us-gaap Revenues
Revenues
419000
us-gaap Revenues
Revenues
2385000
us-gaap Revenues
Revenues
2498000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
68000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
41000
us-gaap Cost Of Revenue
CostOfRevenue
146000
us-gaap Cost Of Revenue
CostOfRevenue
139000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11595000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8558000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31833000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25311000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5666000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6344000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18030000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16073000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
17329000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
14943000
us-gaap Costs And Expenses
CostsAndExpenses
50009000
us-gaap Costs And Expenses
CostsAndExpenses
41523000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16342000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14524000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47624000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39025000
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
916000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
915000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2834000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2741000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
294000
CY2023Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
293000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-68000
us-gaap Gain Loss On Investments
GainLossOnInvestments
276000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2024Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
916000
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1208000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
2755000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
2723000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-15426000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13316000
us-gaap Net Income Loss
NetIncomeLoss
-44869000
us-gaap Net Income Loss
NetIncomeLoss
-36302000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.11
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37621495
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37621495
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35243598
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35243598
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36406635
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36406635
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32586431
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32586431
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
44125000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
465000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15035000
CY2024Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
121000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2364000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-15426000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
46219000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
52534000
CY2023Q1 obio Effect Of Merger And Recapitalization
EffectOfMergerAndRecapitalization
-54302000
CY2023Q1 obio Equity Classified Warrants
EquityClassifiedWarrants
2373000
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-27000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1489000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2023Q1 obio Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
11000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10940000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
99752000
CY2023Q2 obio Stock Issued During Period Value Settlement Of Earnout
StockIssuedDuringPeriodValueSettlementOfEarnout
1000
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-61000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1707000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
64000
CY2023Q2 obio Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
22000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12046000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
89439000
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
19000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3510000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13316000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
79656000
us-gaap Profit Loss
ProfitLoss
-44869000
us-gaap Profit Loss
ProfitLoss
-36302000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
224000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
215000
us-gaap Share Based Compensation
ShareBasedCompensation
7713000
us-gaap Share Based Compensation
ShareBasedCompensation
6706000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
294000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-68000
us-gaap Gain Loss On Investments
GainLossOnInvestments
276000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1270000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3181000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
505000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
473000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
109000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-11000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
88000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-139000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
537000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
458000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3681000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-348000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-514000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-516000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1928000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2018000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37020000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35153000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
183000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
81000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
69401000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
115690000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
52376000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
138073000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16842000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22464000
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
15035000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
23000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
189000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
78000
obio Effect Of Merger Net Of Transaction Costs
EffectOfMergerNetOfTransactionCosts
56810000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15224000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56911000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4954000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-706000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30559000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19784000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25605000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19078000
us-gaap Interest Paid
InterestPaid
1098000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
665000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
27000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-293700000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Areas where significant estimates exist include, but are not limited to, the fair value of stock-based compensation, research and development costs incurred, the fair value of the warrant liability, and the estimated costs to complete the combined performance obligation pursuant to the Terumo Agreement (see Note 4).</p>
CY2024Q3 us-gaap Other Investments
OtherInvestments
2500000
CY2023Q4 us-gaap Other Investments
OtherInvestments
2500000
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2023Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.035
CY2024Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
85000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
307000
CY2023Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
98000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
279000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
4100000
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
11400000
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
54552000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
84628000
obio Assets Transfers Within Levels
AssetsTransfersWithinLevels
0
CY2023 obio Assets Transfers Within Levels
AssetsTransfersWithinLevels
0
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
41223000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
100000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
41321000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
56978000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
17000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
56968000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
5600000
CY2024Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
10000
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
11000
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
102000
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2473000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2323000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1219000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1044000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1254000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1279000
CY2024Q3 us-gaap Depreciation
Depreciation
76000
CY2023Q3 us-gaap Depreciation
Depreciation
71000
us-gaap Depreciation
Depreciation
224000
us-gaap Depreciation
Depreciation
215000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2630000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2661000
CY2024Q3 obio Clinical Trial Accruals
ClinicalTrialAccruals
3228000
CY2023Q4 obio Clinical Trial Accruals
ClinicalTrialAccruals
1409000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1176000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1079000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7034000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5149000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.50
CY2022Q4 obio Warrant Liability Fair Value Disclosure
WarrantLiabilityFairValueDisclosure
2100000
CY2023Q1 obio Warrant Liability Fair Value Disclosure
WarrantLiabilityFairValueDisclosure
2400000
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2089000
CY2023Q1 obio Warrants Exercise During Period Value
WarrantsExerciseDuringPeriodValue
-10000
CY2023Q1 obio Fair Value Adjustments Of Warrants
FairValueAdjustmentsOfWarrants
294000
CY2023Q1 obio Adjustments To Additional Paid In Capital Warrant Reclassified To Equity
AdjustmentsToAdditionalPaidInCapitalWarrantReclassifiedToEquity
-2373000
CY2024Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
8052
CY2019Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
5200
CY2022Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
7800
CY2024Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
6496
us-gaap Operating Lease Payments
OperatingLeasePayments
681000
us-gaap Operating Lease Payments
OperatingLeasePayments
669000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M20D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0991
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
230000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
209000
us-gaap Operating Lease Cost
OperatingLeaseCost
672000
us-gaap Operating Lease Cost
OperatingLeaseCost
626000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
144000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
551000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
682000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
643000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
159000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2179000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
341000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1838000
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
469000
us-gaap Interest Expense Debt
InterestExpenseDebt
1400000
us-gaap Interest Expense Debt
InterestExpenseDebt
0
CY2024Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
0
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1200000
CY2023Q2 obio Earnout First Milestone
EarnoutFirstMilestone
4000000
CY2023Q2 obio Earn Out Shares First Milestone Rounded Off
EarnOutSharesFirstMilestoneRoundedOff
3999987
CY2023Q2 us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
500000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14189122
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13170211
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001558370-24-015313-index-headers.html Edgar Link pending
0001558370-24-015313-index.html Edgar Link pending
0001558370-24-015313.txt Edgar Link pending
0001558370-24-015313-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
obio-20240930.xsd Edgar Link pending
obio-20240930x10q.htm Edgar Link pending
obio-20240930x10q001.jpg Edgar Link pending
obio-20240930xex10d1.htm Edgar Link pending
obio-20240930xex10d2.htm Edgar Link pending
obio-20240930xex10d3.htm Edgar Link pending
obio-20240930xex31d1.htm Edgar Link pending
obio-20240930xex31d2.htm Edgar Link pending
obio-20240930xex32d1.htm Edgar Link pending
obio-20240930xex32d2.htm Edgar Link pending
obio-20240930xex4d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
obio-20240930_cal.xml Edgar Link unprocessable
obio-20240930_def.xml Edgar Link unprocessable
obio-20240930_lab.xml Edgar Link unprocessable
obio-20240930_pre.xml Edgar Link unprocessable
obio-20240930x10q_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable